KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Shares Outstanding (Weighted Average) (2020 - 2025)

Royalty Pharma's Shares Outstanding (Weighted Average) history spans 6 years, with the latest figure at $429.8 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) fell 4.1% year-over-year to $429.8 million; the TTM value through Dec 2025 reached $429.8 million, down 4.1%, while the annual FY2025 figure was $429.8 million, 4.1% down from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $429.8 million at Royalty Pharma, roughly flat from $431.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $451.0 million in Q2 2024 and bottomed at $389.8 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $436.4 million (2022), against an average of $434.2 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) rose 15.74% in 2021 before it dropped 6.1% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $414.8 million in 2021, then increased by 5.59% to $438.0 million in 2022, then grew by 2.2% to $447.6 million in 2023, then grew by 0.13% to $448.2 million in 2024, then decreased by 4.1% to $429.8 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Shares Outstanding (Weighted Average) are $429.8 million (Q4 2025), $431.9 million (Q3 2025), and $423.5 million (Q2 2025).